CH676238A5 - - Google Patents
Download PDFInfo
- Publication number
- CH676238A5 CH676238A5 CH3810/86A CH381086A CH676238A5 CH 676238 A5 CH676238 A5 CH 676238A5 CH 3810/86 A CH3810/86 A CH 3810/86A CH 381086 A CH381086 A CH 381086A CH 676238 A5 CH676238 A5 CH 676238A5
- Authority
- CH
- Switzerland
- Prior art keywords
- hydroxyethoxy
- ethyl
- acid
- diethylene glycol
- dichlorophenylamino
- Prior art date
Links
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000002253 acid Substances 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- -1 diethylene glycol ester Chemical class 0.000 claims description 15
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical class [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- KLLYOVXJTSPZHM-UHFFFAOYSA-N (2,6-dichloroanilino) 2-phenylacetate Chemical compound ClC1=CC=CC(Cl)=C1NOC(=O)CC1=CC=CC=C1 KLLYOVXJTSPZHM-UHFFFAOYSA-N 0.000 claims 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 150000003385 sodium Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 abstract description 6
- 150000007513 acids Chemical class 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Esters of diethylene glycol are obtained by reacting diethylene glycol with acids of general formula I <IMAGE> (wherein n is 0 or 1; R<1> is Cl, H or CH3; R<2> is H, CF3 or CH3; and R<3> is Cl or H) or salts thereof. The esters have anti-inflammatory activity.
Description
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung einer Reihe von Diethylenglykolmonoestern und zwar ein einfaches Verfahren mit charakteristischen Merkmalen, die es gegenüber andern Merkmalen vorteilhaft machen. Die Herstellung der genannten Ester erfolgt in einem einzigen Schritt, indem das Diethylenglykol und die entsprechende Säure verwendet werden, ohne das eine der Hydroxygruppen des Diethylenglykols geschützt werden muss.
Die Erfindung betrifft ebenfalls einen neuen Vertreter der Diethylenglykolmonoester, nämlich den 2-(2,6-Dichlorphenyl-amino)phenylessigsäure-2(2-hydroxyethoxy)-ethylester, welcher eine entzündungshemmende Wirkung besitzt. Schliesslich hat die Erfindung noch eine pharmazeutische Zusammensetzung zum Gegenstand, welche die obige Verbindung als aktive Komponente enthält.
Gegenstand der vorliegenden Erfindung ist demzufolge ein Verfahren zur Herstellung von Diethylenglykolestern der Formel I
EMI1.1
worin n 0 oder 1 ist, R<1> Chlor, Wasserstoff oder Methyl bedeutet, R<2 >Wasserstoff, Trifluormethyl oder Methyl bedeutet und R<3> Chlor oder Wasserstoff darstellt, dass dadurch gekennzeichnet ist, dass man Diethylenglykol direkt mit einer Säure der Formel II
EMI2.1
oder einem Salz davon umsetzt.
Damit der Reaktionsverlauf günstig ist, wird neben der Säure und dem Diethylenglykol, welches in der Regel im Überschuss verwendet wird, ebenfalls Thionylchlorid in stöchiometrischer Menge bezüglich der Säure zugesetzt, in einigen Fällen sogar in höheren Mengen.
Es ist wichtig, darauf hinzuweisen, dass die Reaktion in gleicher Art stattfinden kann, wenn anstelle einer Säure ein Salz, wie beispielsweise Natrium- oder Kaliumsalz verwendet wird.
Die Reaktionstemperatur liegt beispielsweise im Bereich zwischen Zimmertemperatur und Wasserbadtemperatur, d.h. zwischen 20 und 100 DEG C und steht offensichtlich in einem Zusammenhang mit der erforderlichen Zeit zur Beendigung der Reaktion.
Beispiele von Säuren der Formel II, welches mit dem Diethylenglykol umgesetzt werden, sind
2-(2,6-Dichlorphenylamino)-phenylessigsäure (n=l, R<1>=R<3>=Cl, R<2>=H),
2-(3-Trifluormethylphenylamino)benzoesäure (n=O, R<1>=R<3>=H, R<2>= CF3),
2-(2,6-Dichlor-3-methylphenylamino)benzoesäure (n=O, R<1>=R<3>=Cl, R<2>=CH3) oder
2-(2,3-Dimethylphenylamino)benzoesäure (n=O, R<1>=R<2>=CH<3>, R<3>=H).
Wie erwähnt, reagieren die Natrium- und Kaliumsalze dieser Säuren auf ähnliche Weise.
Die Ester, welche durch Umsetzen der obengenannten Säuren Diethylenglykol gegebenenfalls in Gegenwart von Thionylchlorid erhalten werden, sind folgende:
[2-(2-Hydroxyethoxy)ethy]-2-(2,6-dichlorphenylamino)-phenylacetat,
[2-(2-Hydroxyethoxy)ethyl]-2-(3-trifluormethylphenylamino)benzoat,
[2-(2-Hydroxyethoxy)ethyl]-2-(2,6-dichlor-3-methylphenylamino)benzoat und
[2-(2-Hydroxyethoxy)ethyl]-2-(2,3-dimethylphenylamino)benzoat.
Die Rohprodukte der erfindungsgemässen Reaktion von Diethylenglykol mit den Säuren der Formel II oder Salzen davon, in Gegenwart von Thionylchlorid, werden in eine Mischung von Ethylether und Wasser gegeben, wobei die Produkte im organischen Lösungsmittel sehr gut löslich sind. Die Reinigung erfolgt, indem sie durch eine mit Silikagel gefüllte Säule durchgeführt werden. Nach der Säulenchromatographie zeigt das Produkt einen einzigen Fleck bei der Verwendung von Platten mit dem Silikagel-Träger 60 F254, Entwicklung mit Chloroform und Sichtbarmachung mit Licht mit der Wellenlänge 254 nm. Sie zeigen ebenfalls einen einzigen Fleck bei der Hochdruckflüssigchromatographie. Andererseits entsprechen die <1>-H-RMN-Spektren den Erwartungen. Alle zeigen in den IR-Spektren die den Estergruppen entsprechenden Banden.
Gegenstand der Erfindung ist ebenfalls der 2-(2,6-Dichlorphenyl-amino)phenylessigsäure-2-(2-hydroxyethoxy)-ethylester sowie eine pharmazeutische Zusammensetzung, welche diese Verbindung enthält. Pharmakologische Untersuchungen haben ergeben, dass die obige Verbindung eine entzündungshemmende Wirkung besitzt.
Die nachstehenden Beispiele dienen zur Erläuterung der Erfindung.
BEISPIEL 1
Herstellung von [2-(2-Hydroxyethoxy)ethyl]3-2-(2,6-dichlorphenylamino)phenylacetat
Zu 180 ml trockenem Diethylenglykol werden 4 ml Thionylchlorid zugesetzt und kurz darauf werden 15 g Natrium-2-(2,6-dichlorphenylamino)phenylacetat zugegeben. Die Mischung wird bei Zimmertemperatur gerührt und anschliessend werden 200 ml Wasser und 250 ml Ethylether zugegeben und nach dem Rühren der beiden Phasen wird die wässrige Phase abgetrennt und die organische nacheinander mit Wasser, verdünnter Lauge und Wasser gewaschen. Die Etherlösung wird mit Natriumsulfat getrocknet und der Ether abdestilliert. Der ölige Rückstand wird durch Säulenchromatographie auf Silikagel gereinigt, wobei mit Chloroform eluiert wird. Nach Entfernen des Lösungsmittels erhält man 16, 5 g (86%) leicht gelbliches \l, das der Titelverbindung entspricht.
nu (Ester) = 1720 cm<-><1>.
BEISPIEL 2
Herstellung von [2-(2-Hydroxyethoxy)ethyl]-2-(3-trifluormethylphenylamino)benzoat
Zu 80 l trockenem Diethylenglykol werden 3 l Thionylchlorid und 10 kg 2-(3-Trifluormethylphenylamino)benzoesäure zugege ben. Die Mischung wird auf dem Wasserbad während 6 Std. erwärmt. Die resultierende dunkelgrüne Lösung wird abgekühlt und in eine Mischung von Ethylether und Wasser gegeben, wobei das Produkt auf ähnliche Weise wie in Beispiel 1 aufgearbeitet wird. Nach der Reinigung des Produktes erhält man 7,8 kg (59%) eines hellgelben, öligen Produktes.
nu (Ester) = 1683 cm<-><1>.
The present invention relates to a process for the preparation of a series of diethylene glycol monoesters, namely a simple process with characteristic features which make it advantageous over other features. The esters mentioned are prepared in a single step by using the diethylene glycol and the corresponding acid without having to protect one of the hydroxy groups of the diethylene glycol.
The invention also relates to a new representative of the diethylene glycol monoester, namely 2- (2,6-dichlorophenylamino) phenylacetic acid-2 (2-hydroxyethoxy) ethyl ester, which has an anti-inflammatory effect. Finally, the invention relates to a pharmaceutical composition which contains the above compound as an active component.
The present invention accordingly relates to a process for the preparation of diethylene glycol esters of the formula I.
EMI1.1
wherein n is 0 or 1, R 1 is chlorine, hydrogen or methyl, R 2 is hydrogen, trifluoromethyl or methyl and R 3 is chlorine or hydrogen, which is characterized in that diethylene glycol is reacted directly with an acid of formula II
EMI2.1
or a salt thereof.
So that the course of the reaction is favorable, in addition to the acid and the diethylene glycol, which is generally used in excess, thionyl chloride is also added in a stoichiometric amount with respect to the acid, in some cases even in higher amounts.
It is important to point out that the reaction can take place in the same way if a salt such as sodium or potassium salt is used instead of an acid.
The reaction temperature is, for example, in the range between room temperature and water bath temperature, i.e. between 20 and 100 ° C and is obviously related to the time required to complete the reaction.
Examples of acids of the formula II which are reacted with the diethylene glycol are
2- (2,6-dichlorophenylamino) phenylacetic acid (n = 1, R <1> = R <3> = Cl, R <2> = H),
2- (3-trifluoromethylphenylamino) benzoic acid (n = O, R <1> = R <3> = H, R <2> = CF3),
2- (2,6-dichloro-3-methylphenylamino) benzoic acid (n = O, R <1> = R <3> = Cl, R <2> = CH3) or
2- (2,3-dimethylphenylamino) benzoic acid (n = O, R <1> = R <2> = CH <3>, R <3> = H).
As mentioned, the sodium and potassium salts of these acids react in a similar manner.
The esters which are obtained by reacting the above-mentioned acids diethylene glycol, optionally in the presence of thionyl chloride, are as follows:
[2- (2-hydroxyethoxy) ethy] -2- (2,6-dichlorophenylamino) phenylacetate,
[2- (2-hydroxyethoxy) ethyl] -2- (3-trifluoromethylphenylamino) benzoate,
[2- (2-hydroxyethoxy) ethyl] -2- (2,6-dichloro-3-methylphenylamino) benzoate and
[2- (2-hydroxyethoxy) ethyl] -2- (2,3-dimethylphenylamino) benzoate.
The crude products of the reaction according to the invention of diethylene glycol with the acids of the formula II or salts thereof, in the presence of thionyl chloride, are added to a mixture of ethyl ether and water, the products being very readily soluble in the organic solvent. They are cleaned by passing them through a column filled with silica gel. After column chromatography, the product shows a single spot when using plates with silica gel support 60 F254, development with chloroform and visualization with light with a wavelength of 254 nm. They also show a single spot in high pressure liquid chromatography. On the other hand, the <1> -H-RMN spectra meet expectations. All show the bands corresponding to the ester groups in the IR spectra.
The invention also relates to the 2- (2,6-dichlorophenylamino) phenylacetic acid 2- (2-hydroxyethoxy) ethyl ester and a pharmaceutical composition which contains this compound. Pharmacological studies have shown that the above compound has an anti-inflammatory effect.
The following examples serve to illustrate the invention.
EXAMPLE 1
Preparation of [2- (2-Hydroxyethoxy) ethyl] 3-2- (2,6-dichlorophenylamino) phenylacetate
4 ml of thionyl chloride are added to 180 ml of dry diethylene glycol and shortly thereafter 15 g of sodium 2- (2,6-dichlorophenylamino) phenylacetate are added. The mixture is stirred at room temperature and then 200 ml of water and 250 ml of ethyl ether are added, and after the two phases have been stirred, the aqueous phase is separated off and the organic phase is washed in succession with water, dilute alkali and water. The ether solution is dried with sodium sulfate and the ether is distilled off. The oily residue is purified by column chromatography on silica gel, eluting with chloroform. After removal of the solvent, 16.5 g (86%) of slightly yellowish \ l, which corresponds to the title compound.
nu (ester) = 1720 cm <-> <1>.
EXAMPLE 2
Preparation of [2- (2-hydroxyethoxy) ethyl] -2- (3-trifluoromethylphenylamino) benzoate
3 l of thionyl chloride and 10 kg of 2- (3-trifluoromethylphenylamino) benzoic acid are added to 80 l of dry diethylene glycol. The mixture is warmed on the water bath for 6 hours. The resulting dark green solution is cooled and added to a mixture of ethyl ether and water, the product being worked up in a manner similar to that in Example 1. After cleaning the product, 7.8 kg (59%) of a light yellow, oily product are obtained.
nu (ester) = 1683 cm <-> <1>.
Claims (8)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES548226A ES8605220A1 (en) | 1985-10-25 | 1985-10-25 | Esters of diethylene glycol |
Publications (1)
Publication Number | Publication Date |
---|---|
CH676238A5 true CH676238A5 (en) | 1990-12-28 |
Family
ID=8490031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH3810/86A CH676238A5 (en) | 1985-10-25 | 1986-10-22 |
Country Status (9)
Country | Link |
---|---|
JP (1) | JPS62106064A (en) |
BE (1) | BE905666A (en) |
CH (1) | CH676238A5 (en) |
DE (1) | DE3636125A1 (en) |
ES (1) | ES8605220A1 (en) |
FR (1) | FR2589151B1 (en) |
GB (1) | GB2182041B (en) |
IT (1) | IT1197255B (en) |
PT (1) | PT81505B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3811118C1 (en) * | 1988-03-31 | 1989-10-12 | Merckle Gmbh, 7902 Blaubeuren, De | |
US9217066B2 (en) | 2008-03-31 | 2015-12-22 | Ford Global Technologies, Llc | Structural polymer insert and method of making the same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1939112C3 (en) * | 1969-08-01 | 1975-03-06 | Troponwerke Dinklage & Co, 5000 Koeln | Esters of N- (3-trifluoromethylphenyl) anthranilic acid, process for their preparation and pharmacologically active preparations thereof |
DE2735569A1 (en) * | 1977-08-06 | 1979-02-15 | Troponwerke Gmbh & Co Kg | Antiinflammatory and antirheumatic agent prodn. - esp. N-tri:fluoro:methyl-phenyl-anthranilic acid hydroxy-ethoxy-ethyl ester |
DE2834167C2 (en) * | 1978-08-04 | 1984-01-26 | Troponwerke GmbH & Co KG, 5000 Köln | Process for the preparation of 2- (2-hydroxyethoxy) ethyl-N - (α, α, α-trifluoro-m-tolyl) anthranilate |
DE2834168C2 (en) * | 1978-08-04 | 1984-02-09 | Troponwerke GmbH & Co KG, 5000 Köln | Process for the preparation of 2- (2-hydroxyethoxy) ethyl-N - (α, α, α-trifluoro-m-tolyl) anthranilate |
DE2834169C2 (en) * | 1978-08-04 | 1984-02-09 | Troponwerke GmbH & Co KG, 5000 Köln | Process for the preparation of 2- (2-hydroxyethoxy) ethyl-N- (alpha, alpha, alpha -trifluoro-m-tolyl) anthranilate |
DE2926472A1 (en) * | 1979-06-30 | 1981-01-15 | Thomae Gmbh Dr K | NEW BENZOYL DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
IL67445A (en) * | 1982-12-09 | 1985-11-29 | Teva Pharma | Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids |
DE3476550D1 (en) * | 1983-07-21 | 1989-03-09 | Troponwerke Gmbh & Co Kg | Thermoplastics containing antiphlogistics |
US4694105A (en) * | 1983-12-20 | 1987-09-15 | Ciba-Geigy Corporation | Herbicidal alkoxyamino- and polyalkoxyaminodiphenyl ethers |
DE3407507A1 (en) * | 1984-03-01 | 1985-09-05 | A. Nattermann & Cie GmbH, 5000 Köln | Novel o-(2,6-dichloroanilino)phenylacetic acid esters, process for their preparation, and pharmaceutical preparations containing them |
-
1985
- 1985-10-25 ES ES548226A patent/ES8605220A1/en not_active Expired
- 1985-11-15 PT PT81505A patent/PT81505B/en not_active IP Right Cessation
-
1986
- 1986-09-19 IT IT21774/86A patent/IT1197255B/en active
- 1986-10-22 CH CH3810/86A patent/CH676238A5/de not_active IP Right Cessation
- 1986-10-23 DE DE19863636125 patent/DE3636125A1/en not_active Ceased
- 1986-10-24 GB GB8625481A patent/GB2182041B/en not_active Expired
- 1986-10-24 JP JP61252159A patent/JPS62106064A/en active Pending
- 1986-10-27 FR FR868614922A patent/FR2589151B1/en not_active Expired - Lifetime
- 1986-10-27 BE BE0/217337A patent/BE905666A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IT8621774A0 (en) | 1986-09-19 |
GB8625481D0 (en) | 1986-11-26 |
FR2589151B1 (en) | 1990-05-18 |
IT8621774A1 (en) | 1988-03-19 |
GB2182041A (en) | 1987-05-07 |
FR2589151A1 (en) | 1987-04-30 |
GB2182041B (en) | 1989-09-20 |
DE3636125A1 (en) | 1987-04-30 |
PT81505A (en) | 1985-12-01 |
JPS62106064A (en) | 1987-05-16 |
IT1197255B (en) | 1988-11-30 |
PT81505B (en) | 1987-11-11 |
BE905666A (en) | 1987-02-16 |
ES548226A0 (en) | 1986-03-16 |
ES8605220A1 (en) | 1986-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10311850A1 (en) | Preparation of vinpocetin used as vasodilator and nootropic agent, comprises dehydrating vincamine ester to apovincamine derivative and transesterifying | |
EP0086324B1 (en) | Process for preparing ascorbic acid | |
EP0415214A2 (en) | Method for the production of derivatives of alpha-fluoroacrylic acid | |
DE2545511A1 (en) | PROCESS FOR THE PREPARATION OF 1,4-BENZOHYDROCHINONE DERIVATIVES | |
CH676238A5 (en) | ||
DE2036027B2 (en) | Pleuromutilin derivatives and processes for their preparation | |
DE1793462C3 (en) | N-aryl-anthranilic acid esters of monosubstituted gem-diols, process for their preparation and pharmaceutical preparations containing these compounds | |
CH645623A5 (en) | 2-Methyl-3-acetoxy-4,5-bis(halomethyl)pyridines, process for their preparation and process for the preparation of pyridoxin | |
DE2558399C3 (en) | Process for the preparation of 3,6-dichloropicolinic acid | |
DE2338237A1 (en) | PROCESS FOR THE PREPARATION OF 2-ACETAMIDOAETHYL- (3-TRIFLUOROMETHYLPHENOXY) (4-CHLOROPHENYL) ACETATE | |
CH675242A5 (en) | ||
EP0180732B1 (en) | Process for the peparation of 3-acylamino-4-alkoxy-phenyl-beta-hydroxysulfones and -sulfone - sulfuric acid esters | |
DE1156404B (en) | Process for the preparation of thiophosphoric acid esters | |
DE69115849T2 (en) | Process for the preparation of 6- (3-dimethylaminopropionyl) forskolin | |
DE3109532C2 (en) | Stereoisomers 1,4; 3,6-dianhydro-2,5-diazido-2,5-dideoxyhexites, processes for preparing the same, and pharmaceuticals containing these compounds | |
EP0950653A1 (en) | Process for the preparation of potassium monoethylmalonate | |
EP0014478A1 (en) | Process for the preparation of 4,10-dihydro-10-oxo-thieno (3,2-c) (1) benzoxepine-8-alkylacetate | |
DE3411242A1 (en) | ALKYL CHLORINE SULFATE INTERMEDIATE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | |
DE2336913A1 (en) | Perfluoroalkyl modified monoallyl ethers - surfactants, inters and polymer starting materials | |
DE2061430B2 (en) | Process for the preparation of 4-mercaptopyrazolo square bracket to 3,4d square bracket to pyrimidines | |
DE3590057C1 (en) | Process for the preparation of diacyldianhydrohexites | |
DE60112024T2 (en) | Method for isomerizing 6-beta-fluorosteroids to the corresponding 6-alpha derivatives | |
DE192035C (en) | ||
DE2243969C3 (en) | Process for the preparation of the EEZ isomers of 3,11-dimethyl-7-ethyl-2,6,10-tridecatrienoic acid alkyl esters and the compounds used | |
DE2102173A1 (en) | Pyrrolidone carboxylic acid alkyl esters prepn - having therapeutic and cosmetic activity esp for the skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased | ||
PL | Patent ceased |